247 patients produce non-significant overall result for Xanamem
Actinogen Medical’s pivotal XanaMIA trial produced a mixed result: Xanamem showed a small, non-significant benefit across the full 247-patient population, but a prespecified older-patient analysis found a statistically significant difference in disease stabilisation. The company will continue its open-label extension, suspend future Phase 3 spending and seek development partners.
- Non-significant 0.10-point CDR-SB benefit across the full trial at 36 weeks
- 40% of participants over 75 had no disease progression versus 22% on placebo
- Older subgroup showed estimated 30% disease slowing, but this measure was not statistically significant
- No serious adverse events were attributed to Xanamem over 36 weeks
- $18.9 million cash and no debt support a runway into CY2028
Add us as a preferred source on Google
Overall XanaMIA endpoint falls short of significance
Actinogen Medical (ASX:ACW) has found its most encouraging Alzheimer’s signal in the patients most likely to need new treatment, but not in the trial population as a whole. Xanamem was numerically better than placebo on the primary Clinical Dementia Rating Scale-Sum of Boxes endpoint after 36 weeks, with a 0.10-point advantage, but the result was not statistically significant (p=0.65).
The pivotal, double-blind XanaMIA trial enrolled 247 people with mild to moderate Alzheimer’s disease and elevated pTau181 blood biomarkers. The result leaves Actinogen with a potentially useful subgroup finding rather than a clean pivotal readout: the company says small trends towards benefit were also seen in cognition and activities of daily living, but these findings did not establish overall efficacy.
Older participants show stronger stabilisation signal
In a prespecified analysis of participants above the median age of 75, 40% of those receiving Xanamem had no disease progression on the CDR-SB measure, compared with 22% on placebo. That difference was statistically significant (p=0.02).
The same older group produced an estimated 30% slowing of disease progression, based on a 0.39-point CDR-SB advantage at Week 36. However, that result was not statistically significant (p=0.22), an important distinction from the no-progression analysis. Actinogen is using the finding to support a new patent filing focused on older and more advanced Alzheimer’s patients, a population it says accounts for more than 70% of the disease market. The subgroup analysis follows the XanaMIA trial suspension, which was imposed while additional trial data was analysed.
Safety profile supports continued development
Xanamem’s safety profile held up over the full 36-week treatment period. Actinogen said no serious adverse events were attributed to the drug, consistent with its earlier safety observations in more than 500 treated participants. The company also reported no evidence of a reduction in Alzheimer’s biomarkers such as pTau, although it observed trends towards lower GFAP and neurofilament light, markers associated with neuroinflammation and nerve-cell injury.
Early open-label extension data offers another, much smaller signal. The first 29 participants to complete 24 weeks of active Xanamem treatment showed no mean progression on the CDR-SB. Because the extension is uncontrolled and the cohort is small, the result cannot separate treatment effect from other explanations, but Actinogen plans to continue the study and report the next milestone when about 100 participants have reached at least 24 weeks, expected in the first quarter of 2027.
Cash conservation replaces immediate Phase 3 expansion
The trial result has changed the company’s near-term operating plan. Actinogen said it has suspended future Phase 3 expenditure and will focus spending on the open-label extension, further XanaMIA analysis, intellectual-property work, portfolio planning and business-development discussions with potential co-development partners.
Actinogen had $18.9 million in cash and no debt at the announcement date, alongside a significant accrued R&D tax incentive. It expects cash commitments to fall substantially as XanaMIA closes out and says the balance sheet provides a runway into CY2028. The company’s earlier R&D rebate funding boost had also left it with no debt ahead of the readout, giving management more time to test whether the older-patient signal can attract a partner.
For now, Xanamem remains investigational and is not approved by the FDA or any other global regulatory authority. The key question is whether the older-patient result can be reproduced in a larger, appropriately designed study, particularly when the full XanaMIA population did not meet its primary statistical test.
Bottom Line?
Actinogen has bought itself time with a strong balance sheet, but the next OLE milestone and partner interest must determine whether the older-patient signal can become a development plan.
Questions in the middle?
- Will the approximately 100-participant open-label extension preserve the early stabilisation signal in the first quarter of 2027?
- Can Actinogen secure a co-development partner without first confirming the older-patient subgroup in a larger trial?
- How will the suspension of future Phase 3 spending affect the timing and design of Xanamem’s next clinical study?
Sources
1-
ACW XanaMIA Alzheimers trial results (opens in a new tab)Verified company source. Actinogen Medical Limited · 19 Nov 2026 · investors.actinogen.com.au